Remote haemodynamic monitoring in patients with heart failure - Authors' reply
- PMID: 38431345
- DOI: 10.1016/S0140-6736(23)02677-6
Remote haemodynamic monitoring in patients with heart failure - Authors' reply
Conflict of interest statement
JJB received an independent research grant from Abbott for investigator-initiated studies to the hospital and reports speaker engagement or advisory board fees from Astra Zeneca, Abbott, Boehringer Ingelheim, Bayer, Daiichi Sankyo, Novartis, and Vifor. RAdB has received research grants or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, and Roche; and has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novo Nordisk, and Roche. All other authors declare no competing interests.
Comment on
-
Remote haemodynamic monitoring in patients with heart failure.Lancet. 2024 Mar 2;403(10429):807-808. doi: 10.1016/S0140-6736(23)02678-8. Lancet. 2024. PMID: 38431344 No abstract available.
-
Remote haemodynamic monitoring in patients with heart failure.Lancet. 2024 Mar 2;403(10429):808. doi: 10.1016/S0140-6736(23)02679-X. Lancet. 2024. PMID: 38431346 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical